Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 25, 2024
Product Development
Elevidys isn’t slowing innovation in DMD gene therapy
Two gene therapies for Duchenne muscular dystrophy advance to Phase III as a preclinical program attracts pharma acquisition
BioCentury | Nov 20, 2024
Discovery & Translation
Science Spotlight: A new obesity target may avoid nausea, muscle loss
BioCentury’s roundup of translational innovation: Embark/Novo discover new obesity target, Canbridge delivers large DMD gene, and more
BioCentury | Nov 13, 2024
Product Development
Adverse event casts shadow over Neurogene’s Rett syndrome readout
BioCentury’s Clinical Report also analyzes data from Syndax and Gan & Lee, plus pipeline updates from Sarepta, Tango and RAPT
BioCentury | Oct 10, 2024
Discovery & Translation
Science Spotlight: As miRNAs get Nobel Prize, targeting advances continue
BioCentury’s roundup of translational innovation also features Vedanta’s solution to GI infection, Takeda’s exon-skipping delivery tech, and more
BioCentury | Sep 25, 2024
Product Development
Wave claims early lead in second-generation exon 53 skipping
In BioCentury’s latest Clinical Report, Wave gains on DMD data, plus updates from Daiichi and AZ, Black Diamond, Metsera, Biohaven and more
BioCentury | Sep 4, 2024
Product Development
Dyne stumbles on toxicity, leadership concerns
Phase I/II data from exon-skipping DMD therapy show efficacy, but high dose has safety issues
BioCentury | Aug 16, 2024
Finance
Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings
Plus: MeiraGTx, scPharmaceuticals each raise $50M
BioCentury | Aug 14, 2024
Product Development
Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity
Plus: Readouts from Avidity, Apellis/Sobi, Levicept and Merck
BioCentury | Jul 25, 2024
Discovery & Translation
Science Spotlight: Delivering full-length dystrophin, intracellular bioPROTACs, and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 24, 2024
Editor's Commentary
FDA’s different Peter principle problem: prioritizing hope over data
Approval of Elevidys is a sign of systemic problems
Items per page:
1 - 10 of 484